Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluation accurately distinguishes claims supported by the supplied label from claims absent from it, and correctly identifies the 100 mg/4 mL vial strength and labeled dosing schedules.
Category Scores
Accurate Statements
Pricing, reimbursement, and assistance claims are appropriately classified as absent from the label and are not thereby shown to be false.
The supplied sections address dosage and dosage forms, not pricing, reimbursement, insurance, or assistance programs.
Section 2.2 includes 200 mg every 3 weeks and 400 mg every 6 weeks for numerous adult indications, while calling 200 mg the typical dose is a generalization.
Section 2.2 lists these alternative adult regimens for numerous indications; pediatric regimens shown are every 3 weeks.
The claim that a 200 mg vial is used is contradicted by the label, which lists a 100 mg/4 mL single-dose vial.
Section 3 specifies KEYTRUDA injection as 100 mg/4 mL in a single-dose vial.
The claim linking particular pediatric or low-weight adult groups to use of 100 mg vials is only partially supported.
Sections 2.2 and 3 provide pediatric weight-based dosing and identify a 100 mg/4 mL vial, but do not specify that these patient groups receive that vial.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluation correctly identifies the labeled dose schedules and vial strength. It appropriately treats cost and access statements as unverifiable from the supplied label rather than as false.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
No material correction is needed; retain the distinction between a 200 mg administered dose and the labeled 100 mg/4 mL vial strength.